Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E.

Circulation. 2000 Jul 11;102(2):149-56.

3.

Newer antiplatelet agents in acute coronary syndromes.

White HD.

Am Heart J. 1999 Dec;138(6 Pt 2):S570-6. Review.

PMID:
10577464
4.

Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.

McGuire DK, Newby LK.

J Thromb Thrombolysis. 2000 Oct;10(2):111-9. Review.

PMID:
11005932
5.

Sibrafiban.

Dooley M, Goa KL.

Drugs. 1999 Feb;57(2):225-30; discussion 231-2. Review.

PMID:
10188763
6.

Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney.

Levin S, Friedman RM, Cortez E, Hribar J, Nicholas M, Schlessinger S, Fouant M, Khan N.

Toxicol Pathol. 1999 Jan-Feb;27(1):38-43. Review.

7.

[Anticoagulants and antiplatelets].

Ishikawa K, Nakai S.

Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):1042-50. Review. Japanese. No abstract available.

PMID:
12436656
8.

Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.

Adams C, Dhirendra A, Ames PR.

Clin Appl Thromb Hemost. 2011 Feb;17(1):103-5. doi: 10.1177/1076029609343707. Epub 2009 Aug 10. Review.

PMID:
19671560
Items per page

Supplemental Content

Write to the Help Desk